Principia Biopharma appoints Dr Shao-Lee Lin to its Board of Directors

– USA, CA –  Principia Biopharma Inc. (Nasdaq:PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology, today announced the appointment of industry veteran Shao-Lee Lin, M.D., Ph.D., a noted immunologist, rheumatologist, and allergist with significant biopharmaceutical development experience, to its Board of Directors.

“Shao-Lee’s expertise in the medical field comes at a great time for Principia as we continue to develop PRN1008 in both a Phase 3 trial in patients with pemphigus, and a Phase 2 trial in patients with immune thrombocytopenia,” said Martin Babler, Principia’s Chief Executive Officer. “Shao-Lee has extensive experience in developing new medicines, overseeing global development organizations, and leading R&D teams across multiple therapeutic areas.”

About Dr Shao-Lee Lin

Dr. Lin is currently Executive Vice President, head of Research and Development and Chief Scientific Officer of Horizon Pharma plc., with past corporate experiences at AbbVie Inc., Gilead Sciences, Inc., and Amgen Inc.

Dr. Lin is an accomplished pharmaceutical executive, physician and scientist with more than 20 years of academic and clinical research experience. Prior to her current role at Horizon Pharma, Dr. Lin was Vice President, Therapeutic Areas, Development Excellence and International Development at AbbVie. In that role, she led immunology, virology, neuroscience and general medicine across commercial products and pipeline candidates as well as international development across all therapeutic areas. Prior to AbbVie, Dr. Lin was Vice President, Inflammation and Respiratory Development at Gilead Sciences. She also held leadership positions in immunology and other therapeutic areas while at Amgen.

Dr. Lin received her medical degree and doctorate at The Johns Hopkins University School of Medicine and completed fellowships and post-doctoral work in rheumatology, allergy and immunology at the University of California San Diego and The Scripps Clinic and Research Institute. She received her undergraduate degree in biochemistry and chemical engineering from Rice University. Dr. Lin has also been faculty as a Clinical Scholar at The Rockefeller University, and adjunct faculty at Cornell, UCLA, Stanford and Northwestern medical schools.

About Principia Biopharma

Principia is a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to patients with significant unmet medical needs in immunology and oncology. Principia’s proprietary Tailored Covalency platform enables Principia to design and develop reversible and irreversible covalent, small molecule inhibitors with potencies and selectivities that have the potential to rival those of injectable biologics yet maintain the convenience of a pill. PRN1008, a reversible covalent BTK inhibitor, is being evaluated in a Phase 3 clinical trial in patients with pemphigus, an orphan autoimmune disease, and in a Phase 2 clinical trial in patients with immune thrombocytopenia, a rare hematological disease. PRN2246/SAR442168, a covalent BTK inhibitor which crosses the blood-brain barrier, has commenced a Phase 2 clinical trial in patients with multiple sclerosis, and has been partnered with Sanofi for development in that disease and, potentially, for other diseases of the central nervous system. PRN1371, a covalent inhibitor of Fibroblast Growth Factor Receptor is being evaluated in a Phase 1 trial in patients with bladder cancer.

For more information :

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team

here the original post =>